Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody von Reilly, M, Miller, R M, Thomson, M H, Patris, V, Ryle, P, McLoughlin, L, Mutch, P, Gilboy, P, Miller, C, Broekema, M, Keogh, B, McCormack, W, van de Wetering de Rooij, J

Volltext

First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor von DE BRUIJNE, J, VAN DE WETERING DE ROOIJ, J, REESINK, H. W, VAN VLIET, A. A, ZHOU, X. J, TEMAM, M. F, MOLIES, J, CHEN, J, PIETROPAOLO, K, SULLIVAN-BOLYAI, J. Z, MAYERS, D

Volltext

Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor von de Bruijne, Joep, Bergmann, Jilling F, Weegink, Christine J, van Nieuwkerk, Carin M J, de Knegt, Robert J, Komoda, Yasumasa, van de Wetering de Rooij, Jeroen J, van Vliet, Andre, Jansen, Peter L M, Molenkamp, Richard, Schinkel, Janke, Reesink, Hendrik, Janssen, Harry L A

Volltext

The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells von Joly, S, Porcherot, M, Radreau, P, Vonderscher, J, André, P, Meldrum, E, Arold, G, Van de Wetering de Rooij, J, Staner, C, Laveille, C, Scalfaro, P

Volltext

941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS von de Bruijne, J, Bergmann, J, Weegink, C, van Nieuwkerk, K, de Knegt, R, de Rooij, J. van de Wetering, van Vliet, A, Molenkamp, R, Schinkel, J, Reesink, H, Janssen, H

Volltext

SAT-158 - The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells von Joly, S., Porcherot, M., Radreau, P., Vonderscher, J., André, P., Meldrum, E., Arold, G., Van de Wetering de Rooij, J., Staner, C., Laveille, C., Scalfaro, P.

Volltext

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design von HOTHO, Daphne M, DE BRUIJNE, Joep, SCHINKEL, Janke, MOLENKAMP, Richard, DE WETERING DE ROOIJ, Jeroen Van, VLIET, Andre Van, JANSSEN, Harry La, DE KNEGT, Robert J, REESINK, Hendrik W, O'FARRELL, A. Marie, BOYEA, Teresa, JIANKE LI, BRACKEN, Michele, XIN LI, CAMPBELL, David, GULER, Hans-Peter, WEEGINK, Christine J

Volltext

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease von Jennings, Danna, Huntwork‐Rodriguez, Sarah, Vissers, Maurits F.J.M., Daryani, Vinay M., Diaz, Dolores, Goo, Marisa S., Chen, John J., Maciuca, Romeo, Fraser, Kyle, Mabrouk, Omar S., Wetering de Rooij, Jeroen, Heuberger, Jules A.A.C., Groeneveld, Geert Jan, Borin, Marie T., Cruz‐Herranz, Andrés, Graham, Danielle, Scearce‐Levie, Kimberly, De Vicente, Javier, Henry, Anastasia G., Chin, Peter, Ho, Carole, Troyer, Matthew D.

Volltext

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective von Ter Avest, Mendy, Bouwmeester, Romy N, Duineveld, Caroline, Wijnsma, Kioa L, Volokhina, Elena B, van den Heuvel, Lambertus P W J, Burger, David M, Wetzels, Jack F M, van de Kar, Nicole C A J, Ter Heine, Rob

Volltext

Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm von Ono, Nobuhito, Van der Heijden, Ingrid, Scheffer, George L, Van de Wetering, Koen, Van Deemter, Elizabeth, De Haas, Marcel, Boerke, Arjan, Gadella, Bart M, De Rooij, Dirk G, Neefjes, Jacques J, Groothuis, Tom A M, Oomen, Lauran, Brocks, Lenny, Ishikawa, Toshihisa, Borst, Piet

Volltext

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein ( ) von Bain, G, King, C D, Rewolinski, M, Schaab, K, Santini, A M, Shapiro, D, Moran, M, Wetering de Rooij, S, Roffel, A F, Schuilenga‐Hut, P, Milne, G L, Lorrain, D S, Li, Y, Arruda, J M, Hutchinson, J H, Prasit, P, Evans, J F

Volltext

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study von Bouwmeester, Romy N., Duineveld, Caroline, Wijnsma, Kioa L., Bemelman, Frederike J., van der Heijden, Joost W., van Wijk, Joanna A.E., Bouts, Antonia H.M., van de Wetering, Jacqueline, Dorresteijn, Eiske, Berger, Stefan P., Gracchi, Valentina, van Zuilen, Arjan D., Keijzer-Veen, Mandy G., de Vries, Aiko P.J., van Rooij, Roos W.G., Engels, Flore A.P.T., Altena, Wim, de Wildt, Renée, van Kempen, Evy, Adang, Eddy M., ter Avest, Mendy, ter Heine, Rob, Volokhina, Elena B., van den Heuvel, Lambertus P.W.J., Wetzels, Jack F.M., van de Kar, Nicole C.A.J.

Volltext

Implementation of the kidney team at home intervention: Evaluating generalizability, implementation process, and effects von Redeker, Steef, Massey, Emma K., Boonstra, Charlotte, Busschbach, Jan J., Timman, Reinier, Brulez, Harald F. H., Hollander, Daan A. A. M. J., Hilbrands, Luuk B., Bemelman, Frederike, Berger, Stefan P., Wetering, Jacqueline, den Dorpel, René M. A., Dekker‐Jansen, Margriet, Weimar, Willem, Ismail, Sohal Y., Bemelman, J, van der Pant, K.A.M.I., Zwiers, N., Fleur, W., Espineira‐Ramirez, R.Y., Van Milgen‐Adriaens, M., van de Wetering, J., Weimar, W., Massey, E.K., Ismail, S.Y., van Noord‐Haubrich, M.A.A., Busschbach, J.J., Redeker, S., Jansen, D.L., Wageveld‐Sanderson, J.C., van Berkel, I., Clarisse, I., Hollander, D., van de Linde, P., van Dijk, C, de Rooij, A., van den Dorpel, M.A., Versluijs‐Rovers, E.E., van Dongen‐Segeren, G.C.A., Schelfhout, R., van Kooij, A.C., van Krieken, A.S., Koevermans, M.M., van der Marel, T., Brulez, H., Zwiers‐Visser, L., Wisse, E.M., Brouns, N.C.J., Dubbelman, P.S., Holling, B., Smulders, R.M., Dooper, I., Hilbrands, L.B., Lobeek, M., Hopman, S.P.F., Sanders, J.S.F., Berger, S.P., Crop, M.J., Brugman, C.A., Scholten‐Greben, H.G.K., Waijer, J., Kisteman, M.J., Van der Laan, J., Mahangoe, M., Poorterman‐Stokvis, I., Dekker‐Janssen, M.A., Hutten, I.A.M., Potgieter, J.H., Brok, S.J., Kettelerij, H., Boonstra, A.C.

Volltext

Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation von Duineveld, Caroline, Bouwmeester, Romy N., Wijnsma, Kioa L., Bemelman, F.J., van der Heijden, J.W., Berger, S.P., van den Heuvel, L.P.W.J., van de Kar, Nicole C.A.J., Wetzels, Jack F.M., van Zuijlen, A.D., Berger, Dr.SP, Bemelman, F.J., van der Heijden, J.W., van de Wetering, J., de Vries, A.P.J., Wetzels, J.F.M., van Wijk, J.A.E., Bouts, A.H.M., Dorresteijn, E.M., Gracchi, V., Horuz-Engels, F.A.P.T., Keijzer-Veen, M.G., van Rooij, R.W.G., van de Kar, N.C.A.J., van den Heuvel, L.P.

Volltext

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study von Reesink, Hendrik W., Zeuzem, Stefan, Weegink, Christine J., Forestier, Nicole, van Vliet, Andre, van de Wetering de Rooij, Jeroen, McNair, Lindsay, Purdy, Susan, Kauffman, Robert, Alam, John, Jansen, Peter L.M.

Volltext

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 von BOONSTRA, Andre, LIU, Bi-Sheng, BAUMAN, Lisa A, RAHIMY, Mohamad, APPLEMAN, James R, FREDDO, James L, REESINK, Hendrik W, DE KNEGT, Robert J, JANSSEN, Harry La, GROOTHUISMINK, Zwier Ma, BERGMANN, Jilling F, DE BRUIJNE, Joep, HOTHO, Daphne M, HANSEN, Bettina E, VLIET, Andre A.van, DE WETERING DE ROOIJ, Jeroen Van, FLETCHER, Simon P

Volltext

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study von Bouwmeester, Romy N, Duineveld, Caroline, Wijnsma, Kioa L, Bemelman, Frederike J, van der Heijden, Joost W, van Wijk, Joanna A.E, Bouts, Antonia H.M, van de Wetering, Jacqueline, Dorresteijn, Eiske, Berger, Stefan P, Gracchi, Valentina, van Zuilen, Arjan D, Keijzer-Veen, Mandy G, de Vries, Aiko P.J, van Rooij, Roos W.G, Engels, Flore A.P.T, Altena, Wim, de Wildt, Renée, van Kempen, Evy, Adang, Eddy M, ter Avest, Mendy, ter Heine, Rob, Volokhina, Elena B, van den Heuvel, Lambertus P.W.J, Wetzels, Jack F.M, van de Kar, Nicole C.A.J

Volltext

Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study von Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Bemelman, F.J., Heijden, J.W. van der, Wijk, J.A.E. van, Bouts, A.H.M., Wetering, J. van de, Dorresteijn, E., Berger, S.P., Gracchi, V., Zuilen, A.D. van, Keijzer-Veen, M.G., Vries, A.P.J. de, Rooij, R.W.G. van, Engels, F.A.P.T., Altena, W., Wildt, R. de, Kempen, E. van, Adang, E.M., Avest, M. ter, Heine, R. ter, Volokhina, E.B., Heuvel, L.P.W.J. van den, Wetzels, J.F.M., Kar, N.C.A.J. van de

Volltext bestellen